<DOC>
<DOCNO>EP-0639071</DOCNO> 
<TEXT>
<INVENTION-TITLE>
WATER-IN-OIL FLUID VACCINAL EMULSIONS CONTAINING A METABOLIZABLE OIL
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K9107	A61K900	A61K4714	A61K4744	A61K900	A61K9107	A61P3704	A61K4714	A61P3700	A61K3900	A61K3900	A61K4744	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61K	A61P	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K9	A61K9	A61K47	A61K47	A61K9	A61K9	A61P37	A61K47	A61P37	A61K39	A61K39	A61K47	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Metabolizable oil-based water-in-oil vaccinal emulsions which are stable and fluid at 4  DEG C containing: from 5 to 50 v/v % of an antigen-containing aqueous phase, preferably from 12 to 25 v/v %, from 50 to 94 v/v % of an oil phase containing in total or in part a metabolizable oil (vegetable oil, or fatty acid, polyol or alcohol esters), from 0.2 to 20 p/v % of surfactants, preferably from 3 to 8 p/v %, the latter being in total or in part, or in a mixture either polyglycerol esters, said polyglycerol esters being preferably polyglycerol (poly)ricinoleates, or polyoxyethylene ricin oils or else hydrogenated polyoxyethylene ricin oils.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
MERIAL SAS
</APPLICANT-NAME>
<APPLICANT-NAME>
MERIAL
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
RIVIERE MICHEL EMILE ALBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
ROULET CLAUDE
</INVENTOR-NAME>
<INVENTOR-NAME>
RIVIERE, MICHEL, EMILE, ALBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
ROULET, CLAUDE
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Vaccine or immunological medicament formed from
an injectable water-in-oil emulsion possessing immunity

adjuvant activity which has very good tolerance and high
stability which contains an oily phase with emulsifying

agent or emulsifying surface-active agent and an aqueous
phase incorporating a vaccinal antigen or an immunological

active principle, characterized in that the oil
of the oily phase is a metabolizable oil or a mixture of

metabolizable oils and the emulsifying agent, or mixture
of emulsifying agents, is based on ricinoleic acid ester

and/or on polyglyceryl ester and forms, with the
metabolizable oil and the aqueous phase, a stable

emulsion which has a relatively low viscosity of less
than 400 mPa·s at 25°C.
Vaccine or immunological medicament according to
Claim 1, characterized in that the emulsifying agent

comprises ricinoleic acid ester, this ester being, in all
or in part, optionally hydrogenated polyoxyethylenated

castor oil.
Vaccine or immunological medicament according to
Claim 1 or 2, characterized in that the emulsifying agent

comprises polyglyceryl ester, this ester being, in all or
in part, esters of polyglycerol and of natural fatty

acids, such as oleic acid, stearic acid or ricinoleic
acid, or else of branched fatty acids, such as isostearic

acid.
Vaccine or immunological medicament according to
one of Claims 1 to 3, characterized in that the emulsifying

agent comprises a polyglyceryl ester which is an 
ester of polyglycerol and of isostearic acid.
Vaccine or immunological medicament according to
one of Claims 1 to 4, characterized in that the emulsifying

agent comprises optionally hydrogenated polyoxyethylenated
castor oil and an ester of polyglycerol and

of natural fatty acid, such as oleic acid, stearic acid
or ricinoleic acid, or of branched fatty acid, such as

isostearic acid.
Vaccine or immunological medicament according to
one of Claims 1 to 5, characterized in that the emulsifying

agent comprises optionally hydrogenated polyoxyethylenated
castor oil and an ester of polyglycerol and

of isostearic acid.
Vaccine or immunological medicament according to
any one of Claims 1 to 6, characterized in that the

emulsifying agent comprises ricinoleic acid ester, this
ester comprising polyglyceryl polyricinoleate or ricinoleate.
Vaccine or immunological medicament according to
one of Claims 1 to 7, characterized in that the emulsifying

agent comprises optionally hydrogenated polyoxyethylenated
castor oil and polyglyceryl polyricinoleate

or ricinoleate.
Vaccine or immunological medicament according to
one of Claims 2, 5, 6 and 8, characterized in that the

optionally hydrogenated polyoxyethylenated castor oils
have a degree of ethoxylation which is less than 18 mol

of ethylene oxide per mole.
Vaccine or immunological medicament according to
any one of Claims 1 to 9, characterized in that the

emulsifying agents or emulsifying surface-active agents
contain, in all or in part, polyglyceryl esters in a

final proportion of 0.4 to 20 % w/v, preferably between
1 and 10 % and more particularly between 3 and 5 % w/v.
Vaccine or immunological medicament according to
any one of Claims 1 to 10, characterized in that the

polyglycerol has from 2 to 12 glycerol residues and more
particularly from 2 to 5 residues.
Vaccine or immunological medicament according to 
any one of Claims 1 to 11, characterized in that the

polyglyceryl ester can be combined with other surface-active
agents, in particular sorbitan oleate, optionally

hydrogenated polyoxyethylenated castor oils and/or
natural surface-active agents.
Vaccine or immunological medicament according to
Claim 12, characterized in that the natural surface-active

agents are leicthin or else (mono + di)
glycerides, more particularly glycerides of unsaturated

fatty acids (mostly oleic and/or linoleic) and of medium-chain
fatty acids (caprylic and/or capric).
Vaccine or immunological medicament according to
one of Claims 2, 5, 6, 8 and 9, characterized in that the

castor oils are in a final proportion of 0.5 to 25 % w/v,
preferably between 2 and 10 % and more particularly

between 4 and 8 %.
Vaccine or immunological medicament according to
any one of Claims 2, 5, 6, 8, 9 and 14, characterized in

that the optionally hydrogenated polyoxyethylenated
castor oils can be combined with one another and/or with

other surface-active agents belonging to different
chemical series, in particular sorbitan derivatives,

polyoxyethylenated fatty acids or alcohols, glycerides or
lecithins.
Vaccine or immunological medicament according to
any one of Claims 1 to 15, characterized in that the

metabolizable oily phase consists of natural hydrocarbons.
Vaccine or immunological medicament according to
any one of Claims 1 to 15, characterized in that the

metabolizable oily phase consists of vegetable oil of the
triacylglycerol series.
Vaccine or immunological medicament according to
any one of Claims 1 to 15, characterized in that the

metabolizable oily phase consists of esters of fatty
acids and of alcohols.
Vaccine or immunological medicament according to

Claim 18, characterized in that the alcohols entering
into the composition of the esters are, alone or as a 

mixture:

polyols, such as pentaerythritol, glycerol or
propylene glycol;
linear-chain aliphatic monoalcohols, such as
isopropanol and primary alcohols, such as ethanol,

butanol, 1-octanol, 1-decanol or oleyl alcohol;
branched-chain aliphatic monoalcohols, such as
2-ethyl-1-hexanol and so-called isocetyl alcohol.
Vaccine or immunological medicament according to
Claim 18 or 19, characterized in that most of the fatty

acids entering into the composition of the esters are
natural, C6 to C24, acids, preferably oleic and/or

linoleic acid or capric and/or caprylic acid.
Vaccine or immunological medicament according to
Claim 18 or 19, characterized in that most of the fatty

acids entering into the composition of the esters are
diacids such as succinic acid or adipic acid or else

branched fatty acids and more particularly isostearic
acid.
Vaccine or immunological medicament according to
any one of Claims 1 to 21, characterized in that the

aqueous phase of the emulsion is in a proportion such
that the viscosity of the emulsion is acceptable, so that

the said emulsion can easily be injected, preferably
between 5 and 50 % and more particularly between 12 and

25 % v/v.
Vaccine or immunological medicament according to
Claims 1 to 22, characterized in that the emulsion

contains immunity-modulating substances.
Vaccine according to any one of Claims 1 to 23,
characterized in that the aqueous phase of the emulsion

contains, alone or in combination, complete antigens of
viral, bacterial or parasitic origin, or else fractions

of the said antigens, or proteins obtained by genetic
recombination.
Immunological medicament according to any one of
Claims 1 to 23, characterized in that the aqueous phase

contains a foreign protein or a modified protein or a
hapten conjugated to a carrier molecule. 
Vaccine or immunological medicament formed from
an injectable water-in-oil emulsion possessing adjuvant

activity, comprising an aqueous phase incorporating a
vaccinal antigen or an immunological active principle and

an oily phase containing oil and emulsifying agent, the
oil of the oily phase being substantially a metabolizable

oil or a mixture of metabolizable oils and the emulsifying
agent, or mixture of emulsifying agents, is based on

ricinoleic acid ester, in particular optionally hydrogenated
polyoxyethylenated castor oil, and/or on polyglyceryl

ester and forms, as a mixture with the oily
phase, a stable emulsion with a viscosity of less than

400 mPa·s at 25°C.
</CLAIMS>
</TEXT>
</DOC>
